Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Nobutaka, Kunimatsu, Yusuke, Tsutsumi, Rei, Tani, Nozomi, Sato, Izumi, Tanimura, Mai, Nakano, Takayuki, Tanimura, Keiko, Kato, Daishiro, Takeda, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226573/
https://www.ncbi.nlm.nih.gov/pubmed/34072448
http://dx.doi.org/10.3390/medicina57060547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226573/
https://www.ncbi.nlm.nih.gov/pubmed/34072448
http://dx.doi.org/10.3390/medicina57060547

Ejemplares similares